Cutaneous Squamous Cell Carcinoma Staging Study

Overview

Cutaneous squamous cell carcinoma (CSCC) is the second most common form of skin cancer, and one of the most common cancers worldwide. The majority of CSCCs are easily removed by surgery and have excellent prognosis. However, a small subset has poor outcomes, including secondary spread in the body (metastasis) and death. The investigators will look at existing CSCC in people from two UK dermatology centres. The investigators will then evaluate the accuracy of current staging systems in predicting risk of poor outcomes in people. The investigators hope that this project will improve the management of patients with CSCC by validating the predictive power of currently available histological staging classifications for cSCC. In the second stage of the study, The investigators will see whether better prediction tools can be found.

Full Title of Study: “Comparison of the Prognostic Capacity of Existing Staging Systems for Cutaneous Squamous Cell Carcinoma”

Study Type

• Study Type: Observational
• Study Design
  • Time Perspective: Retrospective
• Study Primary Completion Date: November 2024

Interventions

• Other: This is not an interventional study
  • This is not an interventional study

Clinical Trial Outcome Measures

Primary Measures

• Recurrence or metastasis
  • Time Frame: 4 years
  • Cutaneous squamous cell carcinoma locoregional recurrence, nodal or distant metastases
• Metastasis
  • Time Frame: 4 years
  • Cutaneous squamous cell carcinoma nodal or distant metastases

Participating in This Clinical Trial

Inclusion Criteria

• Over 18 years old with diagnosis of CSCC Exclusion Criteria:

• Patients who decline for their data to be used for research purposes

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 120 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

• Lead Sponsor
  • Queen Mary University of London
• Provider of Information About this Clinical Study
  • Sponsor